Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 8/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12366174 | 0.91 | TDP1 (0.41) | TDP1FABP4TTRMCL1TSHR | |
| SCHEMBL12366147 | 0.89 | KMO (0.39) | TDP1FABP4TTRMCL1TSHR | |
| SCHEMBL12366207 | 0.89 | TDP1 (0.41) | TDP1FABP4TTRMCL1TSHR | |
| SCHEMBL12366189 | 0.87 | SLC6A3 (0.46) | SLC6A3 | |
| SCHEMBL12366608 | 0.84 | HTR2B (0.48) | — | |
| SCHEMBL12366040 | 0.83 | TTR (0.39) | TDP1FABP4TTRMCL1 | |
| SCHEMBL12366227 | 0.82 | TDP1 (0.40) | TDP1TTRMCL1TSHR | |
| SCHEMBL12366204 | 0.82 | SRD5A2 (0.46) | TDP1TTRMCL1TSHRMRGPRX4 | |
| SCHEMBL12365227 | 0.82 | TDP1 (0.42) | TDP1TTRMCL1PTPRC | |
| SCHEMBL12366131 | 0.82 | DHODH (0.38) | TDP1TTRPTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | TDP1 378/4885FABP4 1914/4885TTR 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.